Neuraptive Therapeutics Inc. Receives Orphan Drug Designation for its Lead Development Asset

Contributed by: Business Wire

Tags

FDA
Health
Neurology
Clinical Trials
Pharmaceutical
Biotechnology
Orphan Drug Designation for its Lead Development Asset

More Like This

Evan L. Tzanis, Chief Operating Officer and EVP of R&D, Neuraptive Therapeutics, Inc. (Photo: Business Wire)

Neuraptive Therapeutics Receives FDA Breakthrough Therapy Designation for NTX-001 and Provides Update on the Advancements of NTX-001 for the Treatment of Peripheral Nerve Injury Requiring Repair

“The NEUROFUSE Study has yielded promising early clinical results consistent with preclinical studies of NTX-001,” said Evan Tzanis, Chief Operating Officer and EVP of R&D at Neuraptive Therapeutics, Inc. (Photo: Business Wire)

Neuraptive Therapeutics, Inc. Announces Achievement of Proof of Concept in The NEUROFUSE Study of NTX-001 for the Adjunct Treatment of Transected Peripheral Nerves

Neuraptive Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating the Safety and Efficacy of NTX-001 Compared to Standard of Care in the Treatment of Upper Extremity Transected Nerves Requiring Surgical Repair

Evan L. Tzanis, COO and EVP Head of R&D, Neuraptive Therapeutics, Inc. (Photo: Business Wire)

Neuraptive Therapeutics, Inc. Announces Positive 24-Week Data for NTX-001 in the Phase 2 NEUROFUSE Study, Reinforcing Previously Announced Proof of Concept 12-Week Data

Business Wire embedded0

Neuraptive Therapeutics Announces Presentation of Phase 2 Topline Interim Results for NTX-001 at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting

Neuraptive Therapeutics, Inc. Announces Key Organizational Updates to Support the Company’s Advancement Toward Commercialization

PR Newswire associated0

Neurizon Therapeutics Receives Positive Opinion on Orphan Medicinal Product Designation for NUZ-001 in Europe

Curatis on track: submission of orphan drug designation application in the US for lead product candidate